​

MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

ForecastOwnershipFinancialsChartTranscripts

Previous Close

$18.34

52W Range

$5.95 - $62.75

50D Avg

$16.23

200D Avg

$29.85

Market Cap

$1.26B

Avg Vol (3M)

$2.05M

Beta

1.24

Div Yield

-

MLTX Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CH

Employees

100

IPO Date

Oct 20, 2020

Website

MLTX Performance

MLTX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income-$-143.09M$-54.12M
Net Income$-229.10M$-118.94M$-36.01M
EBITDA$-219.85M$-141.71M$-53.75M
Basic EPS$-3.53$-1.89$-0.73
Diluted EPS$-3.53$-1.89$-0.73

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 23Sep 29, 25 | 8:45 PM

Peer Comparison

TickerCompany
RGNXREGENXBIO Inc.
MBXMBX Biosciences, Inc. Common Stock
MGTXMeiraGTx Holdings plc
VSTMVerastem, Inc.
VTYXVentyx Biosciences, Inc.
ERASErasca, Inc.
ABSIAbsci Corporation
OLMAOlema Pharmaceuticals, Inc.
AVBPArriVent BioPharma, Inc. Common Stock
CTMXCytomX Therapeutics, Inc.